Semaglutide and daily life with obesity-related heart failure

The short answer

Two trials found that semaglutide improved reported symptoms and physical limitations in people with obesity and heart failure with preserved ejection fraction. The second trial specifically enrolled people with type 2 diabetes.

What did the first trial find?

STEP-HFpEF randomized 529 participants to weekly semaglutide 2.4 mg or placebo for 52 weeks.

A heart-failure questionnaire improved by 16.6 points with semaglutide and 8.7 with placebo. Higher scores mean fewer symptoms and physical limitations. Average weight changed by −13.3% versus −2.6%.

Participants also improved their six-minute walking distance by 21.5 meters versus 1.2 meters. Serious adverse events occurred in 13.3% versus 26.7%; this is not a count of all side effects.

What about people with type 2 diabetes?

STEP-HFpEF DM separately enrolled 616 people with obesity, the same form of heart failure, and type 2 diabetes for 52 weeks.

Questionnaire scores improved by 13.7 points with semaglutide and 6.4 with placebo. Weight changed by −9.8% versus −3.4%. Serious adverse events occurred in 17.7% versus 28.8%.

What should we take from this?

The findings connect treatment with how people felt and functioned, not just the scale. These were separate trials, so their percentages do not prove that diabetes caused a different treatment response. Neither result should be generalized to every form of heart failure or everyone with obesity.